

TRACON Pharmaceuticals' small molecule TRC102 and antibody TRC105 to be presented at ASCO 2009

May 26, 2009 3:04 PM ET

May 26, 2009

San Diego, CA – May 26, 2009 – TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that Phase 1 clinical results from studies of TRC105 and TRC102 in patients with advanced cancer will be presented at the American Society of Clinical Oncology annual meeting this May 28th and 29th in Orlando, Florida. Both programs target unique pathways with the potential for broad application to a wide variety of cancer types.

TRC105 is a monoclonal antibody that binds CD105 (endoglin), a membrane receptor on endothelial cells that is required for angiogenesis. By inhibiting new blood vessel formation, the antibody is expected to have activity against a wide variety of solid tumors that rely on angiogenesis to grow and metastasize. CD105 is also expressed on cancer stem cells.

TRC102 is a small molecule inhibitor of base excision repair that reverses resistance to commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta®) and as an intravenous agent in combination with temozolomide (Temodar®).

“TRACON remains on schedule to deliver three Phase 2-ready assets in 2009 including two monoclonal antibodies,” commented Charles P. Theuer MD PhD, President and CEO of TRACON Pharmaceuticals. “We are currently engaged in manufacturing and clinical development activities to support comprehensive Phase 2 programs.”

The presentation details are as follows:

TRC105

Abstract Title: Phase 1 study of TRC105 [anti-CD105 (endoglin) antibody] therapy in patients with advanced refractory cancer

Presenter: Lee Rosen, MD, Premiere Oncology – Los Angeles

Date and Time: Friday, May 29, 2009, 2:00 PM – 6:00 PM

Session Title: Developmental Therapeutics

Session Type: Poster Discussion

Abstract Number: 3518

TRC102

Abstract Title: A Phase 1 study of daily oral TRC102 (methoxyamine) to enhance the therapeutic effects of pemetrexed in patients with advanced refractory cancer

Presenter: Steven Anthony, DO, Evergreen Hematology and Oncology

Date and Time: Saturday, May 30, 2009, 8:00 AM – 12:00 PM

Session Title: Developmental Therapeutics

Session Type: Poster Presentation

Abstract Number: 2552

About TRACON

TRACON Pharmaceuticals is a privately held biotechnology company focused on the development of products for oncology and ophthalmology treatment, including agents that inhibit angiogenesis. TRACON addresses unmet needs in these areas with first-in-class product candidates that will complement existing therapies. TRC093 is a monoclonal antibody that binds to cleaved collagen to inhibit angiogenesis and tumor growth that began dosing in a Phase 1 clinical trial

in cancer patients in July, 2007. TRC105 is a monoclonal antibody that binds CD105 (endoglin) to inhibit angiogenesis that began dosing in a Phase 1 clinical trial in cancer patients in January, 2008. TRC102, a small molecule that reverses resistance to chemotherapeutics, began dosing in 2008 in a Phase 1 trial in combination with Temodar® and a Phase 1 trial in combination with Alimta®. Further information about TRACON Pharmaceuticals can be found at www.traconpharma.com.

TRACON Pharmaceuticals Contact:

Delia Alvarez, (858) 550-0780 ext. 232, info@traconpharma.com